Cantargia Interim Report for the period 1 Jan 2015 – 30 June 2015 available

Lund, Sweden 25 August 2015 – Cantargia AB Interim Report for the second quarter 2015 is now available on the company web-site (www.cantargia.com). An extract from the report is presented below.

Significant events in the second quarter of 2015

Notice of the Annual General Meeting was published on the Company’s website in April. The Annual General Meeting was held at Medicon Village on 22 May 2015 and a report from the AGM was published on the same date. At the AGM a resolution was adopted authorising the Board of Directors to decide on the issuance of new shares, on one or several occasions, during the period until the next Annual General Meeting. In April Cantargia published its annual report for the financial year 2014. The annual report is available for download at the Company’s website, www.cantargia.com.

In May Cantargia announced that the Company had received notice that the European Patent Office (EPO) had issued an “intention to grant” for Cantargia’s patent application for IL1RAP as a target molecule for antibody therapy and leukemia diagnostics. Intention to grant essentially means that the EPO is likely to approve the patent application. Before final notice of approval can be received, however, further actions will be required by both parties.

On 1 June 2015 Lars Thorsson took up the position of Vice President Clinical Development at Cantargia. Before joining Cantargia Lars Thorsson worked at Novo Nordisk A/S, where he held the role of Senior Clinical Pharmacology Scientist with responsibility for preparation and implementation of clinical pharmacological studies in development projects.

In June Cantargia received a non-exclusive license to use BioWa’s POTELLIGENT® technology platform for production of its CAN04 drug candidate. BioWa Inc. is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., a leading Japanese pharmaceutical company.

Significant events after the end of the period

At the beginning of July Cantargia announced that the Company had concluded an agreement with Glycotope Biotechnology GmbH for production of Cantargia’s CAN04 drug candidate. Glycotope Biotechnology will be responsible for process development and manufacture in accordance with good manufacturing practices and will produce CAN04 for use in future toxicological studies as well as clinical trials.

In August the respected international journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) published a scientific article on the use of Cantargia’s antibodies in preclinical models of acute myeloid leukemia (AML). The article, entitled “Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia”, documents that Cantargia’s antibodies targeted at IL1RAP have a potent antitumour effect in preclinical models of AML.

First half (1 Jan. 2015 – 30 June 2015)

• Other operating revenue was KSEK 0 (0).
• Earnings after financial items were KSEK -9,059 (-3,707).
• Earnings per share were approximately SEK -0.68 (-20.15).
• The equity/assets ratio was approximately 90 (63) per cent.

Second quarter (1 April 2015 – 30 June 2015)

• Other operating revenue was KSEK 0 (0).
• Earnings after financial items were KSEK -5,432 (-1,839).
• Earnings per share were approximately SEK -0.41 (-10.00).

Definitions

• Earnings per share: Profit for the period divided by 13,394,874 shares as of 30 June 2015.
• Equity/assets ratio: Equity divided by total capital.
• Figures in parentheses refer to same period in the previous year.

For further information, please contact:

Cantargia AB
Göran Forsberg, Ph.D.
CEO
Telephone: +46 46 275 62 60
E-mail: goran.forsberg@cantargia.com

Website: www.cantargia.com

Tags: